STEPHEN STREITFELD: Open Payments
NPI 1306883293 · TUCSON, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,172 in 48 payments from 12 companies in 2025. Trend: 2023 $924 · 2024 $1,061 · 2025 $1,172
Food & beverage: $1,172
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 13 | $272 |
| Neurocrine BioSciences, Inc. | 6 | $211 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 7 | $168 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $136 |
| Teva Pharmaceuticals USA, Inc. | 4 | $121 |
| Lundbeck LLC | 3 | $83 |
| Janssen Pharmaceuticals, Inc | 2 | $58 |
| E.R. Squibb & Sons, L.L.C. | 2 | $43 |
| Almatica Pharma LLC | 1 | $31 |
| Axsome Therapeutics, Inc. | 1 | $21 |
Products named: VRAYLAR, INGREZZA, CAPLYTA, TRINTELLIX, AUSTEDO XR, REXULTI, INVEGA SUSTENNA, COBENFY.
Industry payments across AZ — which companies pay providers there.
